AI assistant
H. Lundbeck A — Director's Dealing 2015
Aug 27, 2015
Preview isn't available for this file type.
Download source fileValby, Denmark, 2015-08-27 13:09 CEST (GLOBE NEWSWIRE) -- Valby, Denmark, 27
August 2015 – H. Lundbeck A/S (Lundbeck) hereby reports transactions made by
executives and persons and legal entities closely associated to them with
shares and linked securities in Lundbeck, cf. Section 28a of the Danish
Securities Trading Act.
Name: Lars Rasmussen
Job position: Member of the Board of Directors
ID code (ISIN code): DK 0010287234
Name of the issuer of the securities: H. Lundbeck A/S
Description of the security: Shares
Nature of the transaction: Purchase of shares
Date of trading: 26 August 2015
Market on which the trading was affected: Nasdaq OMX Copenhagen
Number of traded securities: 20,000
Market price of securities traded: DKK 3,975,456
Persons under obligation to report such transactions are defined as members of
the Executive Management, members of the Board of Directors and other
executives of H. Lundbeck A/S and persons/entities closely associated to them.
Closely associated persons/entities could include but is not limited to:
-- spouse or cohabitant
-- children below the age of 18, provided that the executive is the custody
holder
-- legal entities in which the executive has a controlling influence
Lundbeck contacts
Investors: Media:
Palle Holm Olesen Mads Kronborg
Vice President, Investor Relations Director, Media Relations
[email protected] [email protected]
+45 36 43 24 26 +45 36 43 30 00
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in brain diseases. For more than 50 years, we have been at the
forefront of research within neuroscience. Our key areas of focus are alcohol
dependence, Alzheimer’s disease, bipolar disorder, depression/anxiety,
epilepsy, Huntington’s disease, Parkinson’s disease, schizophrenia and
symptomatic neurogenic orthostatic hypotension (NOH).
An estimated 700 million people worldwide are living with brain disease and far
too many suffer due to inadequate treatment, discrimination, a reduced number
of working days, early retirement and other unnecessary consequences. Every
day, we strive for improved treatment and a better life for people living with
brain disease – we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 6,000 employees in 57 countries are engaged in the entire
value chain throughout research, development, production, marketing and sales.
Our pipeline consists of several late-stage development programs and our
products are available in more than 100 countries. We have research centers in
China, Denmark and the United States and production facilities in China,
Denmark, France and Italy. Lundbeck generated revenue of approximately DKK 13.5
billion in 2014 (EUR 1.8 billion; USD 2.4 billion).
Lundbeck’s shares are listed on the stock exchange in Copenhagen under the
symbol ”LUN”. Lundbeck has a sponsored Level 1 ADR program listed in the US
(OTC) under the symbol ”HLUYY”.
For additional information, we encourage you to visit our corporate site
www.lundbeck.com.
Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our
expectations or forecasts of future events such as new product introductions,
product approvals and financial performance.
Such forward-looking statements are subject to risks, uncertainties and
inaccurate assumptions. This may cause actual results to differ materially from
expectations and it may cause any or all of our forward-looking statements here
or in other publications to be wrong. Factors that may affect future results
include interest rate and currency exchange rate fluctuations, delay or failure
of development projects, production problems, unexpected contract breaches or
terminations, government-mandated or market-driven price decreases for
Lundbeck's products, introduction of competing products, Lundbeck's ability to
successfully market both new and existing products, exposure to product
liability and other lawsuits, changes in reimbursement rules and governmental
laws and related interpretation thereof, and unexpected growth in costs and
expenses.
Certain assumptions made by Lundbeck are required by Danish Securities Law for
full disclosure of material corporate information. Some assumptions, including
assumptions relating to sales associated with product that is prescribed for
unapproved uses, are made taking into account past performances of other
similar drugs for similar disease states or past performance of the same drug
in other regions where the product is currently marketed. It is important to
note that although physicians may, as part of their freedom to practice
medicine in the US, prescribe approved drugs for any use they deem appropriate,
including unapproved uses, at Lundbeck, promotion of unapproved uses is
strictly prohibited.